Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Kaletra

Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 91–92

HOS-109092 · Präparat HOS-093083

91 Pimozide Due to CYP3A inhibition by Concomitant administration of lopinavir/ritonavir, concentrations Kaletra and pimozide is of pimozide are expected to contraindicated as it may increase increase. the risk of serious haematologic abnormalities or other serious adverse effects from this agent (see section 4.3) Quetiapine Due to CYP3A inhibition by Concomitant administration of lopinavir/ritonavir, concentrations Kaletra and quetiapine is of quetiapine are expected to contraindicated as it may increase increase. quetiapine-related toxicity. Benzodiazepines Midazolam Oral Midazolam: Kaletra must not be co-administered AUC: ↑ 13-fold with oral midazolam (see section Parenteral Midazolam: 4.3), whereas caution should be AUC: ↑ 4-fold used with co-administration of Due to CYP3A inhibition by Kaletra and parenteral midazolam. lopinavir/ritonavir If Kaletra is co-administered with parenteral midazolam, it should be done in an intensive care unit (ICU) or similar setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. Dosage adjustment for midazolam should be considered especially if more than a single dose of midazolam is administered. Beta2-adrenoceptor agonist (long acting) Salmeterol Salmeterol: The combination may result in Concentrations are expected to increased risk of cardiovascular increase due to CYP3A inhibition adverse events associated with by lopinavir/ritonavir. salmeterol, including QT prolongation, palpitations and sinus tachycardia. Therefore, concomitant administration of Kaletra with salmeterol is not recommended (see section 4.4). Calcium channel blockers Felodipine, Nifedipine, Felodipine, Nifedipine, Clinical monitoring of therapeutic and Nicardipine Nicardipine: and adverse effects is recommended Concentrations may be increased when these medicines are due to CYP3A inhibition by concomitantly administered with lopinavir/ritonavir. Kaletra. Corticosteroids Dexamethasone Lopinavir: Clinical monitoring of antiviral Concentrations may be decreased efficacy is recommended when due to CYP3A induction by these medicines are concomitantly dexamethasone. administered with Kaletra.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) nifedipine (HOS-086289) nicardipine (HOS-090619) felodipine (HOS-108908) calcium (HOS-085615) salmeterol (HOS-086285) dexamethasone (HOS-084535) pimozide (HOS-085600) midazolam (HOS-086167)